Lithuania: Medical Cannabis Market Overview 2025

Lithuania legalised the manufacture, import, export, and distribution of medical cannabis on 11 October 2018, with the law coming into effect on 1 May 2019. Despite this early legislative progress, implementation has been slow, and as of 2025, no patients have received medical cannabis treatment in the country.

The framework theoretically allows access for patients with cancer, multiple sclerosis, epilepsy, and AIDS, but the absence of approved products, prescriber protocols, and reimbursement mechanisms has prevented the market from becoming operational.

While Lithuania has established the legal foundation for a regulated medical cannabis system, no active patient market or domestic production industry currently exists. The country remains in a regulatory limbo — legally permissive but practically inactive.

Lithuania’s medical cannabis framework is based on amendments to the Law on the Control of Narcotic and Psychotropic Substances, which legalised medical cannabis for therapeutic use and set out the licensing structure for companies involved in the supply chain.

Licensing and Oversight: Licences for manufacturing, wholesale distribution, import, export, and retail of medical cannabis products are issued by the State Medicines Control Agency (SMCA).

The framework permits:

However, the framework prohibits the cultivation of medical cannabis domestically. All raw materials and finished products must therefore be imported.

Key Gaps:

As a result, while the legal framework exists, no practical access pathway for patients or prescribers is currently in place.

Who Can Prescribe? Under the current legal provisions, licensed physicians are permitted to prescribe medical cannabis for a limited number of conditions, including:

In practice, no prescriptions have been issued, as there are no authorised medical cannabis products available in Lithuania.

Dispensation: Although pharmacies are legally permitted to dispense medical cannabis, no supply chain has been established to enable prescription fulfilment.

Reimbursement: There is no reimbursement mechanism for medical cannabis treatment. Patients would be required to pay out-of-pocket once the market becomes active.

Lithuania’s government has signalled limited political momentum to expand the programme or address implementation challenges. Without the approval of medical cannabis products and clear prescriber guidance, the medical cannabis market remains dormant.

Lithuania’s medical cannabis programme remains legislatively established but functionally inactive. The key bottlenecks preventing progress include:

If Lithuania were to introduce enabling regulations for product approval and cultivation, it could transition to a functioning import-based medical cannabis market similar to those of Czech Republic or Poland.

However, without further reform, the Lithuanian framework will remain a legal formality without practical patient benefit.

Get granular market sizing forecasts, patient population data, and competitive intelligence across 31 European markets. Trusted by investors, operators, and regulators across the continent.